The adenomatous polyposis coli (APC) gene is mutated in familial adenomatous polyposis. Mice with a heterozygous APC Min mutation develop multiple intestinal neoplasia (Min) leading to premature death. Early in colorectal carcinogenesis, APC Min/ þ mice show enhanced Akt-mammalian target of rapamycin (mTOR) signaling, which is paralleled by upregulation of oncogenic K þ channels. In this study, we tested the effect of mTOR inhibition with rapamycin on tumor formation in APC Min/ þ mice and evaluated ion channel regulation. We found that continuous long-term rapamycin treatment of APC Min/ þ mice dramatically inhibits intestinal neoplasia. Moreover, although untreated APC Min/ þ mice lose weight, experience intestinal bleeding and succumb to multiple neoplasia by 22.3±1.4 weeks of age, mice treated with rapamycin maintain stable weight and survive long term (39.6 ± 3.4 weeks), with more than 30% surviving >1 year. Impressively, abnormalities in colonic electrolyte transport typical for APC Min/ þ mice are abolished, along with the suppression of epithelial Na þ channel (ENaC) and oncogenic K þ ion channels BK, Elk1 and Erg1, both functionally and at mRNA levels. These results show that continuous prophylaxis by rapamycin markedly inhibits the development of APC mutation-related polyposis, and suggest a novel contributing mechanism of action through the blockade of intestinal oncogenic ion channels.